MedImmune Signs Cancer Pact with Immunocore
MedImmune has entered into a research collaboration with Immunocore to develop novel cancer therapies.
p>MedImmune, the biologics R&D arm of AstraZeneca, has entered into a cancer research collaboration with UK-based biotech company Immunocore. Under the terms of the licensing agreement, both companies will conduct research to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. The platform harnesses the patient’s immune system by directing T cells to target and destroy cancerous cells without damaging healthy cells. Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets.
AstraZeneca and MedImmune will have rights to further develop and commercialize ImmTAC products. Immunocore will receive an upfront payment of $20 million per program and is eligible to receive up to $300 million in development and commercial milestone payments for each target program and significant tiered royalties from successful programs.
Source: AstraZeneca
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
